Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy

Laura Galli, Vincenzo Spagnuolo, Andrea Poli, Stefania Salpietro, Nicola Gianotti, Francesca Cossarini, Alessia Carbone, Silvia Nozza, Simona Bossolasco, Alba Bigoloni, Adriano Lazzarin, Antonella Castagna

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: Previous studies have shown that statins use is associated with a lower mortality risk or occurrence of non-Hodgkin's lymphoma or non-AIDS-defining malignancies (NADMs) in HIV-positive patients. We evaluated the effect of statin therapy on the occurrence of all AIDS-defining malignancy (ADM) and NADM among HIV-positive patients.

Design: A chart study on HIV-1 infected patients attending the Infectious Diseases Department of the San Raffaele Scientific Institute, Italy.

Methods: Incident malignancies diagnosed since antiretroviral treatment (ART) initiation until October 2012 among treated patients not taking statins at ART initiation. Statin therapy had to precede cancer diagnosis, if it occurred. Malignancies that occurred before ART or statin initiation were excluded. Follow-up was calculated since ART initiation until the first cancer diagnosis or loss to follow-up or death or last available visit, whichever occurred first. Results are described as median (interquartile range, IQR).

Results: Five thousand, three hundred and fifty-seven HIV-1 treated patients were included. During 52 663 person-years, 740 (14%) patients had a history of statin use; 375 malignancies occurred: 12 (1.6%) malignancies (0 ADM; 12 NADM, crude incidence rate, 1.3/1000 person-years) among statin users and 363 (7.9%) malignancies (194 ADM; 169 NADM, crude incidence rate, 8.4/1000 person-years) among non-statin users. By multivariate Fine-Gray regression, statin use was associated with a lower risk of cancer [adjusted hazard ratio (95% confidence interval) for ever use: 0.45 (0.17-0.71)].

Conclusion: Among HIV-1 treated patients, statin use was associated with a lower risk of cancer; the benefit was mainly related to AIDS-defining malignancies. Confirmatory studies are needed to consider the residual confounding likely present in this study.

Original languageEnglish
Pages (from-to)2407-2415
Number of pages9
JournalAIDS (London, England)
Volume28
Issue number16
DOIs
Publication statusPublished - 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
HIV-1
Acquired Immunodeficiency Syndrome
Neoplasms
Therapeutics
HIV
Incidence

Keywords

  • AIDS-defining malignancies
  • Cancer
  • HIV
  • HMG-CoA reductase
  • Non-AIDS-defining malignancies
  • Risk
  • Statins

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases
  • Medicine(all)

Cite this

Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. / Galli, Laura; Spagnuolo, Vincenzo; Poli, Andrea; Salpietro, Stefania; Gianotti, Nicola; Cossarini, Francesca; Carbone, Alessia; Nozza, Silvia; Bossolasco, Simona; Bigoloni, Alba; Lazzarin, Adriano; Castagna, Antonella.

In: AIDS (London, England), Vol. 28, No. 16, 2014, p. 2407-2415.

Research output: Contribution to journalArticle

Galli, Laura ; Spagnuolo, Vincenzo ; Poli, Andrea ; Salpietro, Stefania ; Gianotti, Nicola ; Cossarini, Francesca ; Carbone, Alessia ; Nozza, Silvia ; Bossolasco, Simona ; Bigoloni, Alba ; Lazzarin, Adriano ; Castagna, Antonella. / Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. In: AIDS (London, England). 2014 ; Vol. 28, No. 16. pp. 2407-2415.
@article{e9017de853c144f1a16d857ada898ad8,
title = "Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy",
abstract = "Objective: Previous studies have shown that statins use is associated with a lower mortality risk or occurrence of non-Hodgkin's lymphoma or non-AIDS-defining malignancies (NADMs) in HIV-positive patients. We evaluated the effect of statin therapy on the occurrence of all AIDS-defining malignancy (ADM) and NADM among HIV-positive patients.Design: A chart study on HIV-1 infected patients attending the Infectious Diseases Department of the San Raffaele Scientific Institute, Italy.Methods: Incident malignancies diagnosed since antiretroviral treatment (ART) initiation until October 2012 among treated patients not taking statins at ART initiation. Statin therapy had to precede cancer diagnosis, if it occurred. Malignancies that occurred before ART or statin initiation were excluded. Follow-up was calculated since ART initiation until the first cancer diagnosis or loss to follow-up or death or last available visit, whichever occurred first. Results are described as median (interquartile range, IQR).Results: Five thousand, three hundred and fifty-seven HIV-1 treated patients were included. During 52 663 person-years, 740 (14{\%}) patients had a history of statin use; 375 malignancies occurred: 12 (1.6{\%}) malignancies (0 ADM; 12 NADM, crude incidence rate, 1.3/1000 person-years) among statin users and 363 (7.9{\%}) malignancies (194 ADM; 169 NADM, crude incidence rate, 8.4/1000 person-years) among non-statin users. By multivariate Fine-Gray regression, statin use was associated with a lower risk of cancer [adjusted hazard ratio (95{\%} confidence interval) for ever use: 0.45 (0.17-0.71)].Conclusion: Among HIV-1 treated patients, statin use was associated with a lower risk of cancer; the benefit was mainly related to AIDS-defining malignancies. Confirmatory studies are needed to consider the residual confounding likely present in this study.",
keywords = "AIDS-defining malignancies, Cancer, HIV, HMG-CoA reductase, Non-AIDS-defining malignancies, Risk, Statins",
author = "Laura Galli and Vincenzo Spagnuolo and Andrea Poli and Stefania Salpietro and Nicola Gianotti and Francesca Cossarini and Alessia Carbone and Silvia Nozza and Simona Bossolasco and Alba Bigoloni and Adriano Lazzarin and Antonella Castagna",
year = "2014",
doi = "10.1097/QAD.0000000000000443",
language = "English",
volume = "28",
pages = "2407--2415",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "16",

}

TY - JOUR

T1 - Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy

AU - Galli, Laura

AU - Spagnuolo, Vincenzo

AU - Poli, Andrea

AU - Salpietro, Stefania

AU - Gianotti, Nicola

AU - Cossarini, Francesca

AU - Carbone, Alessia

AU - Nozza, Silvia

AU - Bossolasco, Simona

AU - Bigoloni, Alba

AU - Lazzarin, Adriano

AU - Castagna, Antonella

PY - 2014

Y1 - 2014

N2 - Objective: Previous studies have shown that statins use is associated with a lower mortality risk or occurrence of non-Hodgkin's lymphoma or non-AIDS-defining malignancies (NADMs) in HIV-positive patients. We evaluated the effect of statin therapy on the occurrence of all AIDS-defining malignancy (ADM) and NADM among HIV-positive patients.Design: A chart study on HIV-1 infected patients attending the Infectious Diseases Department of the San Raffaele Scientific Institute, Italy.Methods: Incident malignancies diagnosed since antiretroviral treatment (ART) initiation until October 2012 among treated patients not taking statins at ART initiation. Statin therapy had to precede cancer diagnosis, if it occurred. Malignancies that occurred before ART or statin initiation were excluded. Follow-up was calculated since ART initiation until the first cancer diagnosis or loss to follow-up or death or last available visit, whichever occurred first. Results are described as median (interquartile range, IQR).Results: Five thousand, three hundred and fifty-seven HIV-1 treated patients were included. During 52 663 person-years, 740 (14%) patients had a history of statin use; 375 malignancies occurred: 12 (1.6%) malignancies (0 ADM; 12 NADM, crude incidence rate, 1.3/1000 person-years) among statin users and 363 (7.9%) malignancies (194 ADM; 169 NADM, crude incidence rate, 8.4/1000 person-years) among non-statin users. By multivariate Fine-Gray regression, statin use was associated with a lower risk of cancer [adjusted hazard ratio (95% confidence interval) for ever use: 0.45 (0.17-0.71)].Conclusion: Among HIV-1 treated patients, statin use was associated with a lower risk of cancer; the benefit was mainly related to AIDS-defining malignancies. Confirmatory studies are needed to consider the residual confounding likely present in this study.

AB - Objective: Previous studies have shown that statins use is associated with a lower mortality risk or occurrence of non-Hodgkin's lymphoma or non-AIDS-defining malignancies (NADMs) in HIV-positive patients. We evaluated the effect of statin therapy on the occurrence of all AIDS-defining malignancy (ADM) and NADM among HIV-positive patients.Design: A chart study on HIV-1 infected patients attending the Infectious Diseases Department of the San Raffaele Scientific Institute, Italy.Methods: Incident malignancies diagnosed since antiretroviral treatment (ART) initiation until October 2012 among treated patients not taking statins at ART initiation. Statin therapy had to precede cancer diagnosis, if it occurred. Malignancies that occurred before ART or statin initiation were excluded. Follow-up was calculated since ART initiation until the first cancer diagnosis or loss to follow-up or death or last available visit, whichever occurred first. Results are described as median (interquartile range, IQR).Results: Five thousand, three hundred and fifty-seven HIV-1 treated patients were included. During 52 663 person-years, 740 (14%) patients had a history of statin use; 375 malignancies occurred: 12 (1.6%) malignancies (0 ADM; 12 NADM, crude incidence rate, 1.3/1000 person-years) among statin users and 363 (7.9%) malignancies (194 ADM; 169 NADM, crude incidence rate, 8.4/1000 person-years) among non-statin users. By multivariate Fine-Gray regression, statin use was associated with a lower risk of cancer [adjusted hazard ratio (95% confidence interval) for ever use: 0.45 (0.17-0.71)].Conclusion: Among HIV-1 treated patients, statin use was associated with a lower risk of cancer; the benefit was mainly related to AIDS-defining malignancies. Confirmatory studies are needed to consider the residual confounding likely present in this study.

KW - AIDS-defining malignancies

KW - Cancer

KW - HIV

KW - HMG-CoA reductase

KW - Non-AIDS-defining malignancies

KW - Risk

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84916211392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916211392&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000000443

DO - 10.1097/QAD.0000000000000443

M3 - Article

C2 - 25160933

AN - SCOPUS:84916211392

VL - 28

SP - 2407

EP - 2415

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 16

ER -